Shanghai Haohai Biological Technology Co Ltd
SSE:688366

Watchlist Manager
Shanghai Haohai Biological Technology Co Ltd Logo
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Watchlist
Price: 61.2 CNY -1.66% Market Closed
Market Cap: 14.3B CNY
Have any thoughts about
Shanghai Haohai Biological Technology Co Ltd?
Write Note
Shanghai Haohai Biological Technology Co Ltd
/
Cash Flow Statement
/
Cash Paid for Dividends

Shanghai Haohai Biological Technology Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shanghai Haohai Biological Technology Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
Cash Paid for Dividends
-¥73.6m
CAGR 3-Years
17%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash Paid for Dividends
-¥141.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash Paid for Dividends
-¥907.5m
CAGR 3-Years
-711%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash Paid for Dividends
-¥2B
CAGR 3-Years
-31%
CAGR 5-Years
-19%
CAGR 10-Years
-38%
Imeik Technology Development Co Ltd
SZSE:300896
Cash Paid for Dividends
-¥1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shanghai Haohai Biological Technology Co Ltd
Glance View

Market Cap
14.3B CNY
Industry
Biotechnology

Shanghai Haohai Biological Technology Co., Ltd. operates at the cutting edge of the biopharmaceutical industry, specializing in regenerative medicine, medical aesthetics, and other biotechnology applications. Founded on the principles of innovation and science-driven solutions, the company has built an impressive portfolio that underscores its expertise in biological materials. Core to its operations is the development and commercialization of hyaluronic acid products, pivotal in fields such as ophthalmology, wound care, and more recently, dermal fillers for aesthetic treatments. Haohai Biological leverages high-end biotechnological processes to produce its offerings, ensuring that they meet the highest standards of quality and efficacy—a strategy that has allowed it to capture significant market share both domestically within China and beyond its borders. The revenue streams of Haohai Biological are as diversified as its product lines. The company generates income primarily through the sale of its high-margin pharmaceutical and medical device products. It has strategically positioned itself in the burgeoning market for medical aesthetics, where demand for cosmetic enhancements is rapidly growing, fueled by a global shift toward non-invasive procedures. Additionally, its ophthalmic products, crucial for surgeries and various ocular conditions, continue to be significant revenue drivers. Beyond product sales, Haohai invests in licensing its technologies and forging strategic partnerships with international firms, further enhancing its market reach and capitalizing on global biotechnology trends. This multifaceted approach positions the company not only as a producer but as a leader in scientific innovation and commercialization in the biotechnology sector.

Intrinsic Value
81.96 CNY
Undervaluation 25%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Shanghai Haohai Biological Technology Co Ltd's Cash Paid for Dividends?
Cash Paid for Dividends
-73.6m CNY

Based on the financial report for Dec 31, 2023, Shanghai Haohai Biological Technology Co Ltd's Cash Paid for Dividends amounts to -73.6m CNY.

What is Shanghai Haohai Biological Technology Co Ltd's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 5Y
2%

Over the last year, the Cash Paid for Dividends growth was 42%. The average annual Cash Paid for Dividends growth rates for Shanghai Haohai Biological Technology Co Ltd have been 17% over the past three years , 2% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.